Navigation Links
Azur Pharma Announces the Licensing of Niravam, Parcopa, Kemstro and Fluxid From UCB
Date:1/9/2009

DUBLIN, Ireland, January 9 /PRNewswire/ -- Azur Pharma Limited ("Azur Pharma") today announced that it licensed the exclusive U.S. marketing rights for Niravam(R) (alprazolam orally disintegrating tablets), Parcopa(R) (carbidopa-levodopa orally disintegrating tablets), Kemstro(TM) (baclofen orally disintegrating tablets) and Fluxid(TM) (famotidine orally disintegrating tablets) from UCB (Euronext: UCB). Financial terms were not disclosed.

Niravam, Parcopa and Kemstro are central nervous system ("CNS") products. Azur Pharma's CNS business currently markets FazaClo(R) in the U.S. for the management of severely ill schizophrenic patients who fail to respond adequately to standard schizophrenia drug treatments. FazaClo is supplied as an innovative orally disintegrating tablet that uses proprietary formulation technologies licensed from CIMA Labs Inc. ("CIMA"), a subsidiary of Cephalon Inc (NASDAQ: CEPH).

Mr Seamus Mulligan, Chairman and Chief Executive of Azur stated, "We are pleased to add these valuable products to our portfolio. In particular, Niravam, Parcopa and Kemstro represent a broadening of our CNS franchise and are consistent with our approach of improving our products through the application of value added drug delivery technologies."

Niravam and Parcopa have been commercially available in the U.S. since 2005 and 2004, respectively. There is one approved generic competitor to Parcopa. Two ANDAs to Niravam have been filed with the FDA. Kemstro and Fluxid are both FDA approved but not yet commercially available in the U.S.

About Azur Pharma

Azur is a privately held pharmaceutical company dedicated to enhancing patients' lives by developing and marketing pharmaceutical products in specialist therapeutic areas. Azur's strategy is to identify, evaluate, selectively ac
'/>"/>

SOURCE Azur Pharma Limited
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
5. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... Bellevue city councilmember John Stokes ... solutions for people with disabilities on Friday, June ... , The exhibit hall, which is free ... Sunday, will feature leading manufacturers and suppliers of ... eyegaze technologies, computer applications, and home modification equipment. ...
(Date:6/19/2013)... Clinverse, Inc. , a ... trials, today announced it will be exhibiting and ... in Boston, June 24-26, 2013. Clinverse’s eClinical ... fully configurable, cloud-based clinical financial lifecycle system. , ... Clinverse’s eClinical Commerce Network, automates site contract set-up ...
(Date:6/19/2013)... June 19, 2013   NineSigma , Inc., of ... year following its launch, NineSights.com is now ... point for the worldwide community of innovators. ... environmental sustainability experts, NineSights stands out for its large ... scientific and technical disciplines, all vetted by NineSigma. The ...
(Date:6/19/2013)... , June 19, 2013 /PRNewswire/ ... Bureau presents Innovative Drug Delivery ... Technology Licensing Opportunities for Generic ... There are more ... release drugs approved all over ...
Breaking Biology Technology:City of Bellevue, Wash., Welcomes Assistive Technology Exhibit Hall 2Clinverse, Inc. Exhibiting and Showcasing Its Technology at DIA 2013 2NineSigma Evolves Global Open Innovation through Social Media Platform, NineSights 2NineSigma Evolves Global Open Innovation through Social Media Platform, NineSights 3Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies 2Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies 3
... ANNAPOLIS, Md., May 15 PharmAthene, Inc. (NYSE Amex: ... countermeasures against biological and chemical threats, today reported financial ... 31, 2009.For the first quarter of 2009, PharmAthene recognized ... the same period of 2008. Revenues for the ...
... /PRNewswire-Asia-FirstCall/ -- China,Biologic Products, Inc. (OTC Bulletin Board: ... leading plasma-based pharmaceutical companies in the,People,s Republic of ... present at the upcoming China Rising Conference hosted ... May 18, 2009 and the 3rd Annual China,Dragon ...
... ElutraSep, Inc. today announced the commercial launch of the Cryptonite™ ... . , ... Atlanta, GA (PRWEB) ... launch of the Cryptonite™ HV Filter Module for Cryptosporidium and ...
Cached Biology Technology:PharmAthene Reports First Quarter 2009 Financial and Operational Results 2PharmAthene Reports First Quarter 2009 Financial and Operational Results 3PharmAthene Reports First Quarter 2009 Financial and Operational Results 4PharmAthene Reports First Quarter 2009 Financial and Operational Results 5PharmAthene Reports First Quarter 2009 Financial and Operational Results 6PharmAthene Reports First Quarter 2009 Financial and Operational Results 7China Biologic Products to Present at CCG IR's China Rising Conference and Oppenheimer's China Dragon Call Conference in New York 2China Biologic Products to Present at CCG IR's China Rising Conference and Oppenheimer's China Dragon Call Conference in New York 3China Biologic Products to Present at CCG IR's China Rising Conference and Oppenheimer's China Dragon Call Conference in New York 4ElutraSep Inc. Announces the Launch of the Cryptonite™ HV Filter Module for Cryptosporidium and Giardia Testing 2
(Date:6/19/2013)... the most potent physiological anabolic agent for tissue-building ... of lipids, protein and carbohydrates, and inhibiting their ... also plays a major role in stimulating glucose ... metabolized and removed from the blood following meals. ... mechanisms by which insulin regulates glucose uptake in ...
(Date:6/19/2013)... expected to contribute to a very large and potentially ... a University of Michigan ecologist and colleagues who released ... Chesapeake Bay. , The Gulf forecast, one of two ... for an oxygen-depleted, or hypoxic, region of between 7,286 ... the 10 largest on record. , The low end ...
(Date:6/18/2013)... United Kingdom, the Energy Department,s National Renewable Energy ... recently published a paper describing a novel cellulose-degrading ... quadripunctata , commonly known as the gribble. ... a relatively unique ability to produce their own ... down the biomass they eat. New biomass-degrading enzymes ...
Breaking Biology News(10 mins):Breakthrough research of essential molecule reveals important targets in diabetes and obesity 2U-M researcher and colleagues predict possible record-setting Gulf of Mexico 'dead zone' 2U-M researcher and colleagues predict possible record-setting Gulf of Mexico 'dead zone' 3U-M researcher and colleagues predict possible record-setting Gulf of Mexico 'dead zone' 4Novel enzyme from tiny gribble could prove a boon for biofuels research 2
... an important signaling molecule in plants - as in ... herb as a model plant, researchers have found that ... in plants. In collaborative work with the research ... doctoral student at the Botany Department, University of Delhi, ...
... Press announces the latest addition to its Cumulative Techniques ... Cumitech 46 -- Laboratory Procedures for Diagnosis of ... provide guidance to the laboratory personnel and other members ... ordering and application of tests for the diagnosis and ...
... a neutrophil releases a protein that can suppress glucose ... found. Neutrophils, a type of white blood ... to have a connection with glucose levels. During bacterial ... frequently results in hypoglycemia. In addition, many patients with ...
Cached Biology News:Nitric oxide regulates plants as well as people 2
... a cocktail of 3 siRNAs specifically targeted ... most popular product. The siTrio reagent guarantees ... your target gene when used under standard ... confirmation of optimal transfection with one of ...
... is a compact benchtop and stackable ... controller with a large display screen ... speed. Air circulation inside to evenly ... can be easily calibrated from the ...
... Nonanoyl-N-methylglucamide ... properties. Can be readily removed by ... Purity: ≥98% by HPLC. ... nm): 2 O. CMC 19 ...
...
Biology Products: